Medical stents are generally known. Stents, in combination with coverings, also can be used for the endovascular repair of aneurysms, an abnormal widening or ballooning of a portion of a body lumen which can be related to weakness in the wall of the body lumen. Various stent designs are known in the art. Stents typically are tubular, and are expandable or self-expand from a relatively small diameter to a larger diameter.
Braided stents are popular for bare metal constructs. Covering a braided stent has challenges in that the covering will wrinkle, stretch, or tear if it does not move in tandem with the wires.
According to one example, (“Example 1”), an implantable medical device includes a frame having a plurality of struts overlapping and extending between a proximal end and a distal end of the frame; and a tubular member attached to the frame and including fibrils extending along the plurality of struts and configured to maintain alignment with the plurality of struts.
According to another example, (“Example 2”) further to Example 1, the fibrils of the tubular member are axially aligned with the plurality of struts.
According to another example, (“Example 3”) further to Examples 1 or 2, the fibrils extend in parallel with the plurality of struts.
According to another example, (“Example 4”) further to Examples 1-3, the plurality of struts are braided and extend helically between the proximal end and the distal end of the frame, and the fibrils are configured to coincide with a geometry of the plurality of struts.
According to another example, (“Example 5”) further to Example 4, the geometry of the plurality of struts changes in response to at least one of a length change of the frame and a circumferential change of the frame, and the fibrils are configured to orient with the plurality of struts in a direction extending toward the proximal end of the frame and a direction extending toward the distal end of the frame.
According to another example, (“Example 6”) further to Examples 1-5, the plurality of struts include a first set of struts that extend at a first pitch toward the proximal end and a second set of struts that extend at a second pitch toward the distal end, and the fibrils include a first set of fibrils that extend at approximately the first pitch toward the proximal end and a second set of fibrils that extend at approximately the second pitch toward the distal end.
According to another example, (“Example 7”) further to Example 6, the first set of fibrils overlap with the second set of fibrils throughout the tubular member.
According to another example, (“Example 8”) further to Example 7, the fibrils are configured to shear relative to one another to maintain alignment with the plurality of struts in response to at least one of a length change of the frame and a circumferential change of the frame.
According to another example, (“Example 9”) further to Examples 1-8, the tubular membrane is configured to allow expansion and contraction of the frame in response to at least one of a length change of the frame, a circumferential change of the frame, and angular displacement of the frame.
According to another example, (“Example 10”) further to Example 9, the tubular member is configured to resist residual elastic strain acting against frame deformation in response to at least one of the length change of the frame, the circumferential change of the frame, and the angular displacement of the frame.
According to another example, (“Example 11”), an implantable medical device includes a frame having a plurality of struts overlapping and helically extending between a proximal end and a distal end of the frame; and a tubular member attached to the frame and including a primary strength oriented with the plurality of struts, the tubular member configured to maintain orientation of the primary strength with the plurality of struts in response to a force applied to the frame.
According to another example, (“Example 12”) further to Example 11, the tubular member includes a first set of fibrils aligned with the plurality of struts to form the primary strength of the tubular member and a second set of fibrils unaligned with the plurality of struts.
According to another example, (“Example 13”) further to Example 12, the tubular member includes a greater number of the first set of fibrils than a number of the second set of fibrils.
According to another example, (“Example 14”) further to Examples 12-13, lengths of the first set of fibrils are greater than lengths of the second set of fibrils.
According to another example, (“Example 15”) further to Examples 12-14, the first set of fibrils of the tubular member are axially aligned with the plurality of struts.
According to another example, (“Example 16”) further to Examples 11-14, the tubular member forms a continuous flow lumen.
According to another example, (“Example 17”), a method includes deploying an implantable medical device into a body, the implantable medical device including a frame having a plurality of struts overlapping and extending between a proximal end and a distal end of the frame and a tubular member attached to the frame having fibrils extending along the plurality of struts in alignment with the plurality of struts; and maintaining alignment of the fibrils with the plurality of struts in response to altering a geometry of the stent.
According to another example, (“Example 18”) further to Example 17, maintaining alignment of the fibrils includes the fibrils shearing relative to one another to maintain alignment with the plurality of struts in response to at least one of a length change of the frame and a circumferential change of the frame.
According to another example, (“Example 19”) further to Examples 17 or 18, the fibrils of the tubular member are axially aligned with the plurality of struts.
According to another example, (“Example 20”) further to Examples 17-19, the plurality of struts are braided and extend helically between the proximal end and the distal end of the frame, and the fibrils are configured to coincide with a geometry of the plurality of struts.
According to another example, (“Example 21”), an implantable medical device includes a frame having at least one strut arranged in a first direction; and a tubular member attached to the frame and including a strength element oriented with the at least one strut in the first direction and the strength element is configured to bias the at least one strut in the first direction.
Persons skilled in the art will readily appreciate that various aspects of the present disclosure can be realized by any number of methods and apparatuses configured to perform the intended functions. It should also be noted that the accompanying figures referred to herein are not necessarily drawn to scale, but may be exaggerated to illustrate various aspects of the present disclosure, and in that regard, the figures should not be construed as limiting.
A medical device, consistent with various aspects of the present disclosure, is a device adapted to be inserted into a body and then deployed within the body. Such medical devices may be deployed within an artery or other vessel. Most generally, medical devices according to various examples assist in structurally supporting the host vessel lumen, maintaining patency through the vessel, passageway or opening, repairing vessels having an intimal flap or dissection, or isolating sections of a host vessel lumen, such as aneurysms. The medical devices may be shaped and sized and otherwise customized to fit a particular anatomy, including adjusting its length and inside diameters. The medical devices may include a stent with a framework of struts (or relatively rigid sections) and also may include a graft coupled or attached to the framework of struts.
Grafts or coverings in combination with the stent may help minimize or at least reduce the risk of introduction of emboli into a bloodstream, resist tissue encroachment into the lumen defined by the stent, reduce pressure on a weakened part of a blood vessel to reduce the risk of vessel rupture, and/or to create a conduit for attaching at least two vessels. The grafts or coverings may be made from continuous materials with no holes visible without magnification. Various grafts or coverings may be attached to the luminal (interior) or exterior surface of the stent.
In addition, the medical devices discussed herein may include braided or helical frames. The braided or helical frames may include a plurality of struts that overlap as the plurality of struts extends between ends of the medical devices. During deployment, geometry change, or other shape change of the braided frames, helical frames, or other frames, a graft or covering attached to the stent may encumber the stent's ability to expand. As discussed in further detail below, the medical devices discussed herein include tubular members (e.g., grafts or coverings) that interact and cooperate with the framework (to which the tubular members are attached) to ensure accurate deployment and functioning of the medical devices, for example with an inelastic or substantially inelastic covering or tube.
As shown in
In certain instances, the fibrils 210, 212 of the tubular member 208 are axially aligned with the plurality of struts 102. For example, tubular member may include a first set of fibrils 210 and a second set of fibrils 212 as shown in
In certain instances, the plurality of struts 102 are braided and extend helically between the proximal end 104 and the distal end 106. The fibrils 210, 212 are configured to align with a geometry of the plurality of struts 102. For example, the fibrils 210, 212 extend at the same pitch angle at which the plurality of struts 102 extend. In addition and as noted above, the plurality of struts 102 are angled such that adjacent ones of the plurality of struts 102 extend in intersecting directions to form the braided stent 100. The first strut 214 and the first set of fibrils 212 may extend upward and toward the proximal end 104 at a location on the stent 100, whereas the second strut 216 (adjacent to the first strut 214) and the second set of fibrils 212 extends upward and toward the distal end 106 of the stent 100 at that particular location.
In addition to being aligned with the plurality of struts 102, the fibrils 210, 212 are configured to maintain alignment with the plurality of struts 102. The fibrils, for example, maintain alignment with the plurality of struts 102 when the stent 100 changes configuration, geometry, or shape as is described in further detail with reference to
As noted above with reference to
In certain instances, a geometry of the plurality of struts 102 changes in response to at least one of a length change of the stent 100 (e.g., the frame), a circumferential change of the stent 100, or angular displacement of the struts of the stent 100. Similarly, the fibrils 210, 212 are configured to orient with the plurality of struts 102. The fibrils 210, 212 and the plurality of struts 102 orient in a direction extending toward the proximal end 104 of the stent 100 and a direction extending toward the distal end 106 of the stent 100. In certain instances, the plurality of struts 102 include a first set of struts, represented by the first strut 214, that extend at a first pitch toward the proximal end 104 and a second set of struts, represented by the second strut 216, that extend at a second pitch toward the distal end 106. Similarly, the first set of fibrils 210 extend at approximately the first pitch toward the proximal end 104 and the second set of fibrils 212 extend at approximately the second pitch toward the distal end 106. As shown in comparing
In certain instances, the first set of fibrils 210 overlap with the second set of fibrils 212 throughout the tubular member 208. In response to at least one of a length change of the stent 100, a circumferential change of the stent 100 (e.g., as shown comparing
In certain instances, the fibrils 210, 212 being configured to maintain orientation with the plurality of struts 102 allows the stent 100 to expand and contract in response to at least one of a length change of the frame, a circumferential change of the stent 100, or angular displacement of the struts of the stent 100. The fibrils 210, 212 do not otherwise encumber or restrict the ability of the stent 100 to change geometry or expand and contract. More specifically and in certain instances, the tubular member 208, by way of the fibrils 210, 212, is configured to resist residual elastic strain acting against stent 100 deformation in response to at least one of the length change of the frame, the circumferential change of the stent 100, or angular displacement of the struts of the stent. The tubular member 208 does not include residual elastic strain that acts against the stent 100 changing geometry under deformation of the stent 100.
The tubular member 208 may include non-oriented fibrils 318 in addition to the fibrils 210, 212 that are not oriented with the plurality of struts 102. The non-oriented fibrils 318 (represented by the open space between the fibrils 210, 212) may fill connect and fill space between the fibrils 210, 212. The non-oriented fibrils 318 are those fibrils of the tubular member 208 that are not oriented or aligned with primary strength of the tubular member 208.
The fibrils 210, 212 that are aligned with struts 102 of the stent 100 may have a greater strength than fibrils or nodes that connect the strength fibrils together For example, the tubular member can be made from a film that has a force to break strength direction of 1.06 kgf/cm and a force to break transverse direction strength of 0.024 kgf/cm as measured by a tensile testing machine. Other ratios of strength to transverse direction may be used dependent on application. For example a ratio of strength direction to transverse direction may be 30, 35, 40, 45, 50, 55, 60 or more. In addition, the fibrils 210, 212 that are aligned with struts 102 of the stent 100 also have a greater length greater than lengths of the fibrils that are unaligned with the struts 102 of the stent 100 and also maintain alignment with the struts 102 of the stent 100.
In certain instances, the tubular member 208 may include a single set of fibrils 210 that are aligned with struts 102 of the stent 100. The tubular member 208 may have a single strength direction oriented with the stent 100.
As shown in
As shown in
The illustrative medical device shown in
As shown in
In addition to being aligned with the plurality of struts 102, the fibrils 210, 212 are configured to maintain alignment with the plurality of struts 102. The fibrils, for example, maintain alignment with the plurality of struts 102 when the stent 100 changes configuration, geometry, or shape.
Suitable materials for use in in the tubular member 208 may include, without limitation, fluoropolymers (especially polytetrafluoroethylene (PTFE) and fluorinated ethylene propylene (FEP)), polyethylenes, polyethylene terephthalate (PET), nylon, polyurethane, polypropylene, polyester, polyimide, etc., as well as composite materials combining these and/or other materials to achieve the desired strength and compliance characteristics. Expanded PTFE (ePTFE) is believed to be most preferred for many applications.
Depending on applications, tubular members of the present disclosure may be constructed from a continuous material, such as continuous films, tapes, or sheets of materials. Alternatively, the tubular members may include discontinuous structures, such as sheets or tapes that include holes or slits therein, or even materials formed from weaves, knits, or other open structures.
Consistent with various aspects of the present disclosure, frames discussed herein may be made from a variety of materials. These materials comprise metals, such as nitinol, stainless steel, tantalum, titanium, tungsten, gold, platinum, iridium, rhodium and alloys thereof or pyrolytic carbon. Other materials comprise polymers such as polyurethane, high density polyethylene, polypropylene, and poly(dimethyl siloxane). Further still, the frames may be formed from biocompatible polymers that are bio-resorbable (e.g., bio-erodible or bio-degradable). Bio-resorbable materials are preferably selected from the group consisting of any hydrolytically degradable and/or enzymatically degradable biomaterial. Examples of suitable degradable polymers include, but are not limited to, polyhydroxybutyrate/polyhydroxyvalerate copolymers (PHV/PHB), polyesteramides, polylactic acid, hydroxy acids (i.e. lactide, glycolide, hydroxybutyrate), polyglycolic acid, lactone based polymers, polycaprolactone, poly(propylene fumarate-co-ethylene glycol) copolymer (aka fumarate anhydrides), polyamides, polyanhydride esters, polyanhydrides, polylactic acid/polyglycolic acid with a calcium phosphate glass, polyorthesters, silk-elastin polymers, polyphosphazenes, copolymers of polylactic acid and polyglycolic acid and polycaprolactone, aliphatic polyurethanes, polyhydroxy acids, polyether esters, polyesters, polydepsidpetides, polysaccharides, polyhydroxyalkanoates, and copolymers thereof. Further still, the tubes may be formed of a polycarbonate material, such as, for example, tyrosine-derived polycarbonates, tyrosine-derived polyarylates, iodinated and/or brominated tyrosine-derived polycarbonates, iodinated brominated tyrosine-derived polyarylates polyhydroxy acids, polyorthoesters, polyether esters, polyesters, polyamides, polyesteramides, polydepsidpetides, aliphatic polyurethanes, polysaccharides, polyhydroxyalkanoates, and copolymers thereof.
Additionally, the frames could be comprised of any number of other polymers. In another embodiment, metals and polymers may be used to fabricate said tube in a composite, laminate reinforced material, or one that is simply coated with the material. Depending on desired characteristics, tubes may be constructed of materials with specific attributes. For example, in applications where the tube will be expanded and must remain so with little or no creep or re-constriction (that is it must “lock in place”), plastically deformable materials may be chosen for monolithic constructs. Conversely, should a tube need to remain compliant, meaning remaining capable of some degree of radial re-contraction and re-expansion, elastic materials may be chosen. It will be recognized that combining materials with different functional or behavioral attributes may be effected in selected instances. The configuration of the tubes of the invention may be varied to produce selected benefits. In one embodiment, the components making up the frames (the struts) are asymmetrically wrapped along the entire length of the frame. However, in other embodiments, asymmetrically-wrapped frames can be interspersed and connected to torsionally-stable symmetrically-wrapped tube sections, the latter serving to transmit torque.
Persons skilled in the art will readily appreciate that various aspects of the present disclosure can be realized by any number of methods and apparatus configured to perform the intended functions. It should also be noted that the accompanying figures referred to herein are not necessarily drawn to scale, but may be exaggerated to illustrate various aspects of the present disclosure, and in that regard, the figures should not be construed as limiting.
This application national phase application of PCT Application No. PCT/US2018/054915, internationally filed on Oct. 9, 2018, which claims the benefit of U.S. Provisional Application No. 62/569,805, filed Oct. 9, 2017, the entire contents of which are incorporated herein by reference for all purposes.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2018/054915 | 10/9/2018 | WO |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2019/074869 | 4/18/2019 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 3953566 | Gore | Apr 1976 | A |
| 4187390 | Gore | Feb 1980 | A |
| 4332035 | Mano | Jun 1982 | A |
| 4877661 | House et al. | Oct 1989 | A |
| 4955899 | Della et al. | Sep 1990 | A |
| 5026513 | House et al. | Jun 1991 | A |
| 5064435 | Porter | Nov 1991 | A |
| 5071609 | Tu et al. | Dec 1991 | A |
| 5476589 | Bacino | Dec 1995 | A |
| 5534007 | St et al. | Jul 1996 | A |
| 5549663 | Cottone, Jr. | Aug 1996 | A |
| 5673102 | Suzuki et al. | Sep 1997 | A |
| 5708044 | Branca | Jan 1998 | A |
| 5718973 | Lewis et al. | Feb 1998 | A |
| 5720776 | Chuter et al. | Feb 1998 | A |
| 5749852 | Schwab et al. | May 1998 | A |
| 5752934 | Campbell et al. | May 1998 | A |
| 5759192 | Saunders | Jun 1998 | A |
| 5769884 | Solovay | Jun 1998 | A |
| 5772884 | Tanaka et al. | Jun 1998 | A |
| 5788626 | Thompson | Aug 1998 | A |
| 5814405 | Branca et al. | Sep 1998 | A |
| 5824043 | Cottone, Jr. | Oct 1998 | A |
| 5843158 | Lenker et al. | Dec 1998 | A |
| 5843161 | Solovay | Dec 1998 | A |
| 5843171 | Campbell et al. | Dec 1998 | A |
| 5853419 | Imran | Dec 1998 | A |
| 5925061 | Ogi et al. | Jul 1999 | A |
| 5935162 | Dang | Aug 1999 | A |
| 5957974 | Thompson et al. | Sep 1999 | A |
| 6010529 | Herweck et al. | Jan 2000 | A |
| 6013854 | Moriuchi | Jan 2000 | A |
| 6042588 | Munsinger et al. | Mar 2000 | A |
| 6042605 | Martin et al. | Mar 2000 | A |
| 6042606 | Frantzen | Mar 2000 | A |
| 6110198 | Fogarty et al. | Aug 2000 | A |
| 6156064 | Chouinard | Dec 2000 | A |
| 6161399 | Jayaraman | Dec 2000 | A |
| 6165211 | Thompson | Dec 2000 | A |
| 6174329 | Callol et al. | Jan 2001 | B1 |
| 6190406 | Duerig et al. | Feb 2001 | B1 |
| 6217609 | Haverkost | Apr 2001 | B1 |
| 6245012 | Kleshinski | Jun 2001 | B1 |
| 6261320 | Tam et al. | Jul 2001 | B1 |
| 6261620 | Leadbeater | Jul 2001 | B1 |
| 6315791 | Gingras et al. | Nov 2001 | B1 |
| 6336937 | Vonesh et al. | Jan 2002 | B1 |
| 6352552 | Levinson et al. | Mar 2002 | B1 |
| 6379382 | Yang | Apr 2002 | B1 |
| 6423091 | Hojeibane | Jul 2002 | B1 |
| 6436132 | Patel et al. | Aug 2002 | B1 |
| 6461665 | Scholander | Oct 2002 | B1 |
| 6488701 | Nolting et al. | Dec 2002 | B1 |
| 6541589 | Baillie | Apr 2003 | B1 |
| 6620190 | Colone | Sep 2003 | B1 |
| 6626939 | Burnside et al. | Sep 2003 | B1 |
| 6673102 | Vonesh et al. | Jan 2004 | B1 |
| 6673107 | Brandt et al. | Jan 2004 | B1 |
| 6716239 | Sowinski | Apr 2004 | B2 |
| 6730120 | Berg et al. | May 2004 | B2 |
| 6755856 | Fierens et al. | Jun 2004 | B2 |
| 6758858 | Mccrea et al. | Jul 2004 | B2 |
| 6890350 | Walak | May 2005 | B1 |
| 7022132 | Kocur | Apr 2006 | B2 |
| 7049380 | Chang et al. | May 2006 | B1 |
| 7083642 | Sirhan et al. | Aug 2006 | B2 |
| 7105018 | Yip et al. | Sep 2006 | B1 |
| 7306729 | Bacino et al. | Dec 2007 | B2 |
| 7419678 | Falotico | Sep 2008 | B2 |
| 7462675 | Chang et al. | Dec 2008 | B2 |
| 7531611 | Sabol et al. | May 2009 | B2 |
| 7704274 | Boyle et al. | Apr 2010 | B2 |
| 7789908 | Sowinski et al. | Sep 2010 | B2 |
| 7811314 | Fierens et al. | Oct 2010 | B2 |
| 7815763 | Fierens et al. | Oct 2010 | B2 |
| 7887562 | Young et al. | Feb 2011 | B2 |
| 7927364 | Fierens et al. | Apr 2011 | B2 |
| 7927365 | Fierens et al. | Apr 2011 | B2 |
| 7935141 | Randall et al. | May 2011 | B2 |
| 7967829 | Gunderson et al. | Jun 2011 | B2 |
| 8048440 | Chang et al. | Nov 2011 | B2 |
| 8545525 | Surti et al. | Oct 2013 | B2 |
| 8585753 | Scanlon et al. | Nov 2013 | B2 |
| 8728103 | Surti et al. | May 2014 | B2 |
| 8801774 | Silverman | Aug 2014 | B2 |
| 8936634 | Irwin et al. | Jan 2015 | B2 |
| 9241695 | Peavey et al. | Jan 2016 | B2 |
| 9345601 | Jantzen et al. | May 2016 | B2 |
| 9399085 | Cleek et al. | Jul 2016 | B2 |
| 9554786 | Carley et al. | Jan 2017 | B2 |
| 9681948 | Levi et al. | Jun 2017 | B2 |
| 9737422 | Armstrong et al. | Aug 2017 | B2 |
| 9795496 | Armstrong et al. | Oct 2017 | B2 |
| 9833343 | Burnside et al. | Dec 2017 | B2 |
| 9839540 | Armstrong et al. | Dec 2017 | B2 |
| 9931193 | Cully et al. | Apr 2018 | B2 |
| 10166128 | Armstrong et al. | Jan 2019 | B2 |
| 10279084 | Goepfrich et al. | May 2019 | B2 |
| 10335298 | Armstrong et al. | Jul 2019 | B2 |
| 10507124 | Armstrong et al. | Dec 2019 | B2 |
| 20010032009 | Layne | Oct 2001 | A1 |
| 20010053929 | Vonesh et al. | Dec 2001 | A1 |
| 20020038140 | Yang et al. | Mar 2002 | A1 |
| 20020076542 | Kramer et al. | Jun 2002 | A1 |
| 20020161388 | Samuels et al. | Oct 2002 | A1 |
| 20020198588 | Armstrong et al. | Dec 2002 | A1 |
| 20030055494 | Bezuidenhout et al. | Mar 2003 | A1 |
| 20030060871 | Hill et al. | Mar 2003 | A1 |
| 20030180488 | Lim et al. | Sep 2003 | A1 |
| 20040024442 | Sowinski et al. | Feb 2004 | A1 |
| 20040024448 | Chang et al. | Feb 2004 | A1 |
| 20040044400 | Cheng et al. | Mar 2004 | A1 |
| 20040044401 | Bales et al. | Mar 2004 | A1 |
| 20040093065 | Yachia et al. | May 2004 | A1 |
| 20040098095 | Burnside | May 2004 | A1 |
| 20040133266 | Clerc et al. | Jul 2004 | A1 |
| 20040162606 | Thompson | Aug 2004 | A1 |
| 20040170782 | Wang et al. | Sep 2004 | A1 |
| 20040224442 | Grigg | Nov 2004 | A1 |
| 20040260277 | Maguire | Dec 2004 | A1 |
| 20050080476 | Gunderson et al. | Apr 2005 | A1 |
| 20050137680 | Ortiz et al. | Jun 2005 | A1 |
| 20050273149 | Tran et al. | Dec 2005 | A1 |
| 20050283224 | King | Dec 2005 | A1 |
| 20060009835 | Osborne et al. | Jan 2006 | A1 |
| 20060015171 | Armstrong | Jan 2006 | A1 |
| 20060036311 | Nakayama et al. | Feb 2006 | A1 |
| 20060106337 | Blankenship | May 2006 | A1 |
| 20060118236 | House et al. | Jun 2006 | A1 |
| 20060135985 | Cox et al. | Jun 2006 | A1 |
| 20060161241 | Barbut et al. | Jul 2006 | A1 |
| 20060190070 | Dieck et al. | Aug 2006 | A1 |
| 20060259133 | Sowinski et al. | Nov 2006 | A1 |
| 20060271091 | Campbell et al. | Nov 2006 | A1 |
| 20060276883 | Greenberg et al. | Dec 2006 | A1 |
| 20070012624 | Bacino et al. | Jan 2007 | A1 |
| 20070060999 | Randall et al. | Mar 2007 | A1 |
| 20070088421 | Loewen | Apr 2007 | A1 |
| 20070129786 | Beach et al. | Jun 2007 | A1 |
| 20070207186 | Scanlon et al. | Sep 2007 | A1 |
| 20070207816 | Spain, Jr. | Sep 2007 | A1 |
| 20070208421 | Quigley | Sep 2007 | A1 |
| 20070213800 | Fierens et al. | Sep 2007 | A1 |
| 20070250146 | Cully et al. | Oct 2007 | A1 |
| 20070250153 | Cully et al. | Oct 2007 | A1 |
| 20070254012 | Ludwig et al. | Nov 2007 | A1 |
| 20080051876 | Ta et al. | Feb 2008 | A1 |
| 20080097301 | Alpini et al. | Apr 2008 | A1 |
| 20080097401 | Trapp et al. | Apr 2008 | A1 |
| 20080097579 | Shanley et al. | Apr 2008 | A1 |
| 20080097582 | Shanley et al. | Apr 2008 | A1 |
| 20080119943 | Armstrong et al. | May 2008 | A1 |
| 20080319531 | Doran et al. | Dec 2008 | A1 |
| 20090005854 | Huang et al. | Jan 2009 | A1 |
| 20090030499 | Bebb et al. | Jan 2009 | A1 |
| 20090036976 | Beach et al. | Feb 2009 | A1 |
| 20090043373 | Arnault et al. | Feb 2009 | A1 |
| 20090104247 | Pacetti | Apr 2009 | A1 |
| 20090182413 | Burkart et al. | Jul 2009 | A1 |
| 20090306762 | Mccullagh et al. | Dec 2009 | A1 |
| 20090306766 | Mcdermott et al. | Dec 2009 | A1 |
| 20100016940 | Shokoohi et al. | Jan 2010 | A1 |
| 20100094394 | Beach et al. | Apr 2010 | A1 |
| 20100094405 | Cottone | Apr 2010 | A1 |
| 20100106240 | Duggal et al. | Apr 2010 | A1 |
| 20100159171 | Clough | Jun 2010 | A1 |
| 20100211166 | Miller et al. | Aug 2010 | A1 |
| 20100241214 | Holzer et al. | Sep 2010 | A1 |
| 20100256738 | Berglund | Oct 2010 | A1 |
| 20100286760 | Beach et al. | Nov 2010 | A1 |
| 20100305682 | Furst | Dec 2010 | A1 |
| 20110009953 | Luk et al. | Jan 2011 | A1 |
| 20110087318 | Daugherty et al. | Apr 2011 | A1 |
| 20120323211 | Ogle et al. | Dec 2012 | A1 |
| 20130131780 | Armstrong et al. | May 2013 | A1 |
| 20130183515 | White | Jul 2013 | A1 |
| 20130184807 | Kovach et al. | Jul 2013 | A1 |
| 20130197624 | Armstrong et al. | Aug 2013 | A1 |
| 20130204347 | Armstrong et al. | Aug 2013 | A1 |
| 20130245745 | Vong et al. | Sep 2013 | A1 |
| 20130253466 | Campbell et al. | Sep 2013 | A1 |
| 20130297003 | Pinchuk | Nov 2013 | A1 |
| 20140121746 | Kusleika et al. | May 2014 | A1 |
| 20140135897 | Cully et al. | May 2014 | A1 |
| 20140172066 | Goepfrich et al. | Jun 2014 | A1 |
| 20140180402 | Bruchman et al. | Jun 2014 | A1 |
| 20150005870 | Kovach et al. | Jan 2015 | A1 |
| 20150157770 | Cully et al. | Jun 2015 | A1 |
| 20150313871 | Li et al. | Nov 2015 | A1 |
| 20160015422 | De et al. | Jan 2016 | A1 |
| 20160184079 | Scutti et al. | Jun 2016 | A1 |
| 20170065400 | Armstrong et al. | Mar 2017 | A1 |
| 20170105854 | Treacy et al. | Apr 2017 | A1 |
| 20170106176 | Taft et al. | Apr 2017 | A1 |
| 20170216062 | Armstrong et al. | Aug 2017 | A1 |
| 20180177583 | Cully et al. | Jun 2018 | A1 |
| 20190125517 | Cully et al. | May 2019 | A1 |
| 20190209739 | Goepfrich et al. | Jul 2019 | A1 |
| 20190216592 | Cully et al. | Jul 2019 | A1 |
| 20200022828 | Armstrong et al. | Jan 2020 | A1 |
| 20200179663 | Mcdaniel et al. | Jun 2020 | A1 |
| 20210038413 | Cully et al. | Feb 2021 | A1 |
| 20210068996 | Armstrong et al. | Mar 2021 | A1 |
| 20210077246 | Cully et al. | Mar 2021 | A1 |
| 20210138121 | Cully et al. | May 2021 | A1 |
| 20210236139 | Connor | Aug 2021 | A1 |
| Number | Date | Country |
|---|---|---|
| 2462509 | Apr 2003 | CA |
| 101420913 | Apr 2009 | CN |
| 101926699 | Dec 2010 | CN |
| 201744060 | Feb 2011 | CN |
| 102015009 | Apr 2011 | CN |
| 103945796 | Jul 2014 | CN |
| 105025848 | Nov 2015 | CN |
| 0293090 | Nov 1988 | EP |
| 0313263 | Apr 1989 | EP |
| 0582870 | Feb 1994 | EP |
| 0775472 | May 1997 | EP |
| 0815806 | Jan 1998 | EP |
| 0893108 | Jan 1999 | EP |
| 1666003 | Jun 2006 | EP |
| 1946721 | Jul 2008 | EP |
| 2255750 | Dec 2010 | EP |
| 02-000645 | Jan 1990 | JP |
| 09-241412 | Sep 1997 | JP |
| 11-197252 | Jul 1999 | JP |
| 11-290448 | Oct 1999 | JP |
| 11-512635 | Nov 1999 | JP |
| 2001-509702 | Jul 2001 | JP |
| 2007-526098 | Sep 2007 | JP |
| 2008-506459 | Mar 2008 | JP |
| 2008-173461 | Jul 2008 | JP |
| 2010-500107 | Jan 2010 | JP |
| 2010-504174 | Feb 2010 | JP |
| 2010-535075 | Nov 2010 | JP |
| 2015-513931 | May 2015 | JP |
| 2018-134425 | Aug 2018 | JP |
| 2019-048083 | Mar 2019 | JP |
| 2021-122433 | Aug 2021 | JP |
| 2124986 | Jan 1999 | RU |
| 9413224 | Jun 1994 | WO |
| 9416802 | Aug 1994 | WO |
| 9505555 | Feb 1995 | WO |
| 9509586 | Apr 1995 | WO |
| 9607370 | Mar 1996 | WO |
| 9640348 | Dec 1996 | WO |
| 9710871 | Mar 1997 | WO |
| 9926558 | Jun 1999 | WO |
| 0041649 | Jul 2000 | WO |
| 0047271 | Aug 2000 | WO |
| 0164278 | Sep 2001 | WO |
| 0174272 | Oct 2001 | WO |
| 0260506 | Aug 2002 | WO |
| 0303946 | Jan 2003 | WO |
| 0320175 | Mar 2003 | WO |
| 2004000375 | Dec 2003 | WO |
| 2006019626 | Feb 2006 | WO |
| 2006058322 | Jun 2006 | WO |
| 2008021002 | Feb 2008 | WO |
| 2008028964 | Mar 2008 | WO |
| 2008036870 | Mar 2008 | WO |
| 2008049045 | Apr 2008 | WO |
| 2008021006 | Aug 2008 | WO |
| 2008097589 | Aug 2008 | WO |
| 2009017827 | Feb 2009 | WO |
| 2009100210 | Aug 2009 | WO |
| 2009108355 | Sep 2009 | WO |
| 2010006783 | Jan 2010 | WO |
| 2010008570 | Jan 2010 | WO |
| 2010030766 | Mar 2010 | WO |
| 2010132707 | Nov 2010 | WO |
| 2010150208 | Dec 2010 | WO |
| 2011098565 | Aug 2011 | WO |
| 2011132634 | Oct 2011 | WO |
| 2012011261 | Jan 2012 | WO |
| 2012099979 | Jul 2012 | WO |
| 2012158944 | Nov 2012 | WO |
| 2013074663 | May 2013 | WO |
| 2013074990 | May 2013 | WO |
| 2013109337 | Jul 2013 | WO |
| 2013138789 | Sep 2013 | WO |
| 2017038145 | Mar 2017 | WO |
| 2019074869 | Apr 2019 | WO |
| Entry |
|---|
| International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2018/054915, mailed on Apr. 2, 2019, 18 pages. |
| Nakayama, Yasuhide. Microporous Stent Achieves Brain Aneurysm Occlusion Without Disturbing Branching Flow. NeuroNews Nov. 2012; 8:1-2. |
| Nishi S, Nakayama Y, Ishibashi-Ueda H, Okamoto Y, Yoshida M. Development of microporous self-expanding stent grafts for treating cerebral aneurysms: designing micropores to control intimal hyperplasia. J Artif Organs 2011; 14:348-356. |
| International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2018/054915, mailed on Apr. 23, 2020, 14 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20200237497 A1 | Jul 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62569805 | Oct 2017 | US |